THERAPEUTIC COMPOSITION AND RELATED METHODS
A composition. The composition includes a compound of Formula (I) HOCH 2 —(═CHOH═) n —CH2NR 1 R 2 (I) wherein R 1 and R 2 are independently selected from the group consisting of a hydrogen atom, an alkyl group, C(O)R 3 , and SO 2 R 4 , wherein at least one of R 1 and R 2 is C(O)R 3 or SO 2 R 4 , R 3 and R 4 are selected from the group consisting of an alkyl group having seven carbon atoms, an alkyl group having eight carbon atoms, and an alkyl group having nine carbon atoms, and n is an integer from about 2 to about wherein a concentration of the compound of Formula (I) is more than its critical micelle concentration; and an antimicrobial agent selected from the group consisting of a biguanide antimicrobial agent and a polymeric, cationic, non-micelle forming antimicrobial material; wherein a concentration of the antimicrobial agent is no more than 5 wt %.
1 . A composition, comprising:
a compound of Formula (I)
HOCH 2 —(═CHOH═) n —CH2NR 1 R 2 (I)
wherein R 1 and R 2 are independently selected from the group consisting of a hydrogen atom, an alkyl group, C(O)R 3 , and SO 2 R 4 ;
wherein at least one of R 1 and R 2 is C(O)R 3 or SO 2 R 4 , R 3 and R 4 are selected from the group consisting of an alkyl group having seven carbon atoms, an alkyl group having eight carbon atoms, and an alkyl group having nine carbon atoms, and n is an integer from about 2 to about 5;
wherein a concentration of the compound of Formula (I) is more than its critical micelle concentration; and
an antimicrobial agent selected from the group consisting of a biguanide antimicrobial agent and a polymeric, cationic, non-micelle forming antimicrobial material;
wherein a concentration of the antimicrobial agent is no more than 5 wt %.
2 . The composition of claim 1 , wherein the concentration of the compound of Formula (I) is more than 120% of its critical micelle concentration .
3 . The composition of claim 1 , wherein the concentration of the compound of Formula (I) is more than 150% of its critical micelle concentration.
4 . The composition of claim 1 , wherein the concentration of the compound of Formula (I) is more than 180% of its critical micelle concentration.
5 . A composition, comprising:
a compound of Formula (I)
HOCH 2 —(═CHOH═) n —CH2NR 1 R 2 (I)
wherein R 1 and R 2 are independently selected from the group consisting of a hydrogen atom, an alkyl group, C(O)R 3 , and SO 2 R 4 ,
wherein at least one of R 1 and R 2 is C(O)R 3 or SO 2 R 4 , R 3 and R 4 are selected from the group consisting of an alkyl group having seven carbon atoms, an alkyl group having eight carbon atoms, and an alkyl group having nine carbon atoms, and n is an integer from about 2 to about 5;
wherein a concentration of the compound of Formula (I) is more than 0.2 wt %; and
an antimicrobial agent selected from the group consisting of a biguanide antimicrobial agent and a polymeric, cationic, non-micelle forming antimicrobial material;
wherein a concentration of the antimicrobial agent is no more than 5 wt %.
6 . The composition of claim 5 , wherein the concentration of the compound of Formula (I) is more than 0.6 wt %.
7 . The composition of claim 5 , wherein the concentration of the compound of Formula (I) is more than 1.8 wt %.
8 . The composition of claim 1 , wherein the concentration of the antimicrobial agent is no more than 4 wt %.
9 . The composition of claim 1 , wherein the concentration of the antimicrobial agent is no more than 3 wt %.
10 . The composition of claim 1 , further comprising a glucamine compound.
11 . The composition of claim 10 , wherein the glucamine compound is selected from the group of D-glucamine, N-methyl-D-glucamine, N-Ethyl-D-Glucamine, N-Propyl-Glucamine, N-Butyl-D-Glucamine, N-octyl-D-glucamine, and combinations thereof.
12 . The composition of claim 1 , further comprising a glucosamine compound.
13 . The composition of claim 12 , wherein the glucosamine compound is selected from the group of D-Glucosamine Hydrochloride, D-Glucosamine Sulfate, D-Glucosamine Phosphate, D-Glucosamine gluconate and combinations thereof.
14 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier or solvent selected from the group consisting of water, alcohol, glycerol, polyethylene glycol, triethanolamine, methoxypropanol, isopropanol, ethyl acetate, polypropylene glycol and a combination thereof.
15 . The composition of claim 1 , wherein the compound of Formula (I) is MEGA-8, MEGA-9, or MEGA-10.
16 . The composition of claim 1 , further comprising a binder.
17 . The composition of any one of claim 16 , wherein the binder is natural polysaccharides and derivatives selected from murein, pectins, hyaluronate, chondroitin-4-sulfate, dermatan sulfate, keratan sulfate, heparin, heparan sulfate, hydroxyethyl cellulose, hydroxypropyl cellulose, guar gum, and combinations thereof.
18 . The composition of claim 1 , further comprising sugar-alcohol humectant including xylitol, sorbitol, mannitol and erythritol.
19 . The composition of claim 1 , wherein the composition is in a form selected from the group consisting of a solution, a dispersion, a suspension, an emulsion, a solid, a paste, a foam, a gel, a spray, a wipe, a mitt and a brush.
20 . A method, comprising:
providing the composition of claim 1 ; and
applying the composition to a surface of a subject or a medical device.